These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11364907)

  • 1. Fortovase approved: new saquinavir formulation.
    James JS
    AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New formulation of saquinavir (Fortovase) is more effective.
    Tam CW
    Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.
    TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608
    [No Abstract]   [Full Text] [Related]  

  • 4. Saquinavir as Fortovase: why does it matter?
    Trapnell CB
    AIDS Clin Care; 1998 May; 10(5):37, 40. PubMed ID: 11365428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goodbye, Invirase. Hello, Fortovase.
    Vazquez E
    Posit Aware; 1998; 9(1):45-6. PubMed ID: 11365001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soft gel saquinavir has high exposure.
    AIDS Alert; 1997 Dec; 12(12):143-4. PubMed ID: 11364835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roche brings new formulation of saquinavir to FDA. Food and Drug Administration.
    Cadman J
    GMHC Treat Issues; 1997; 11(4/5):8. PubMed ID: 11364377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 11. Efavirenz and Fortovase.
    Baker R
    BETA; 1998 Jul; ():9. PubMed ID: 11365572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
    van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
    Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The medical merry-go-round: drugs for 1998 are new but not novel.
    Gilden D
    GMHC Treat Issues; 1997-1998 Winter; 12(1):18-25. PubMed ID: 11364984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New formulation--fewer tablets--optimal effect].
    Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
    Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
    Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
    Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K
    Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763
    [No Abstract]   [Full Text] [Related]  

  • 20. Saquinavir (Fortovase or Invirase).
    Res Initiat Treat Action; 2000 Mar; 6(1):24-5. PubMed ID: 11708182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.